

Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/ABCB062845BBEN.html>

Date: May 2024

Pages: 139

Price: US\$ 6,499.00 (Single User License)

ID: ABCB062845BBEN

Abstracts

The 7 major atherosclerotic cardiovascular disease markets reached a value of US\$ 23.5 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 29.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.15% during 2024-2034.

The atherosclerotic cardiovascular disease market has been comprehensively analyzed in IMARC's new report titled "Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Atherosclerotic cardiovascular disease (ASCVD) is a prevalent medical condition characterized by the progressive buildup of plaque within the arteries, leading to reduced blood flow and potential blockages. This ailment primarily occurs in the coronary arteries, causing health complications, such as heart attacks and strokes. The symptoms of the disorder can vary depending on the affected regions and the extent of plaque buildup. Some common indications include chest pain (angina), shortness of breath, fatigue, weakness, etc. In a few cases, the disease may remain asymptomatic until a significant blockage occurs, leading to a sudden and severe event like a heart attack. The diagnosis of ASCVD involves a comprehensive evaluation of a patient's medical history, risk factors, and physical examination. The healthcare provider may often utilize various diagnostic tests and procedures, such as cholesterol and lipid level assessments, stress tests, electrocardiograms (ECGs), and imaging techniques like angiography or coronary CT scans, to confirm the diagnosis.

The escalating prevalence of plaque formation, which can cause hardening and narrowing of the arteries, resulting in reduced blood flow, is primarily driving the atherosclerotic cardiovascular disease market. In addition to this, the inflating utilization of effective medications, including statins, cholesterol absorption inhibitors, antiplatelet

agents, etc., for managing the symptoms of the condition and preventing further damage is creating a positive outlook for the market. Moreover, the widespread implementation of lifestyle modifications, such as adopting healthy diets, regular exercise, and smoking cessation, to reduce cholesterol levels, promote weight loss, and improve cardiovascular health, is also propelling the market growth. Apart from this, the increasing utilization of minimally invasive procedures, like angioplasty and stent placement, that can unclog blocked arteries and restore blood flow in patients is acting as another significant growth-inducing factor. Additionally, the rising demand for gene therapy, which involves introducing functional genetic material into cells to replace or rectify the genes responsible for high cholesterol, is also augmenting the market growth. Furthermore, the emerging popularity of regenerative medicines, since they hold the potential to repair and regenerate damaged blood vessels and cardiac tissue, is expected to drive the atherosclerotic cardiovascular disease market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the atherosclerotic cardiovascular disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for atherosclerotic cardiovascular disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the atherosclerotic cardiovascular disease market in any manner.

Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

Countries Covered

United States

Germany

France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the atherosclerotic cardiovascular disease market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the atherosclerotic cardiovascular disease market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current atherosclerotic cardiovascular disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report: Market Insights

How has the atherosclerotic cardiovascular disease market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the atherosclerotic cardiovascular disease market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the atherosclerotic cardiovascular disease market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of atherosclerotic cardiovascular disease across the seven major markets?

What is the number of prevalent cases (2018-2034) of atherosclerotic cardiovascular disease by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of atherosclerotic cardiovascular disease by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with atherosclerotic cardiovascular disease across the seven major markets?

What is the size of the atherosclerotic cardiovascular disease patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of atherosclerotic cardiovascular disease?

What will be the growth rate of patients across the seven major markets?

Atherosclerotic Cardiovascular Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for atherosclerotic cardiovascular disease drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the atherosclerotic cardiovascular disease market?

What are the key regulatory events related to the atherosclerotic cardiovascular disease market?

What is the structure of clinical trial landscape by status related to the atherosclerotic cardiovascular disease market?

What is the structure of clinical trial landscape by phase related to the atherosclerotic cardiovascular disease market?

What is the structure of clinical trial landscape by route of administration related to the atherosclerotic cardiovascular disease market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - INTRODUCTION

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

5 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - DISEASE OVERVIEW

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

6 PATIENT JOURNEY

7 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - EPIDEMIOLOGY AND PATIENT POPULATION

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
 - 7.2.1 Epidemiology Scenario (2018-2023)
 - 7.2.2 Epidemiology Forecast (2024-2034)
 - 7.2.3 Epidemiology by Age (?2018-2034?)
 - 7.2.4 Epidemiology by Gender (?2018-2034?)
 - 7.2.5 Diagnosed Cases (?2018-2034?)
 - 7.2.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.3 Epidemiology Scenario - United States
 - 7.3.1 Epidemiology Scenario (2018-2023)
 - 7.3.2 Epidemiology Forecast (2024-2034)
 - 7.3.3 Epidemiology by Age (?2018-2034?)
 - 7.3.4 Epidemiology by Gender (?2018-2034?)
 - 7.3.5 Diagnosed Cases (?2018-2034?)
 - 7.3.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.4 Epidemiology Scenario - Germany
 - 7.4.1 Epidemiology Scenario (2018-2023)
 - 7.4.2 Epidemiology Forecast (2024-2034)
 - 7.4.3 Epidemiology by Age (?2018-2034?)
 - 7.4.4 Epidemiology by Gender (?2018-2034?)
 - 7.4.5 Diagnosed Cases (?2018-2034?)
 - 7.4.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.5 Epidemiology Scenario - France
 - 7.5.1 Epidemiology Scenario (2018-2023)
 - 7.5.2 Epidemiology Forecast (2024-2034)
 - 7.5.3 Epidemiology by Age (?2018-2034?)
 - 7.5.4 Epidemiology by Gender (?2018-2034?)
 - 7.5.5 Diagnosed Cases (?2018-2034?)
 - 7.5.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.6 Epidemiology Scenario - United Kingdom
 - 7.6.1 Epidemiology Scenario (2018-2023)
 - 7.6.2 Epidemiology Forecast (2024-2034)
 - 7.6.3 Epidemiology by Age (?2018-2034?)
 - 7.6.4 Epidemiology by Gender (?2018-2034?)
 - 7.6.5 Diagnosed Cases (?2018-2034?)
 - 7.6.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.7 Epidemiology Scenario - Italy
 - 7.7.1 Epidemiology Scenario (2018-2023)
 - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (?2018-2034?)
- 7.7.4 Epidemiology by Gender (?2018-2034?)
- 7.7.5 Diagnosed Cases (?2018-2034?)
- 7.7.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.8 Epidemiology Scenario - Spain
 - 7.8.1 Epidemiology Scenario (2018-2023)
 - 7.8.2 Epidemiology Forecast (2024-2034)
 - 7.8.3 Epidemiology by Age (?2018-2034?)
 - 7.8.4 Epidemiology by Gender (?2018-2034?)
 - 7.8.5 Diagnosed Cases (?2018-2034?)
 - 7.8.6 Patient Pool/Treated Cases (?2018-2034?)
- 7.9 Epidemiology Scenario - Japan
 - 7.9.1 Epidemiology Scenario (2018-2023)
 - 7.9.2 Epidemiology Forecast (2024-2034)
 - 7.9.3 Epidemiology by Age (?2018-2034?)
 - 7.9.4 Epidemiology by Gender (?2018-2034?)
 - 7.9.5 Diagnosed Cases (?2018-2034?)
 - 7.9.6 Patient Pool/Treated Cases (?2018-2034?)

8 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

9 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - UNMET NEEDS

10 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - KEY ENDPOINTS OF TREATMENT

11 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - MARKETED PRODUCTS

- 11.1 List of Atherosclerotic Cardiovascular Disease Marketed Drugs Across the Top 7 Markets
 - 11.1.1 Leqvio (Inclisiran)- Novartis Pharmaceuticals
 - 11.1.1.1 Drug Overview
 - 11.1.1.2 Mechanism of Action
 - 11.1.1.3 Regulatory Status
 - 11.1.1.4 Clinical Trial Results

- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Lodoco (Colchicine)- Agepha Pharma
 - 11.1.2.1 Drug Overview
 - 11.1.2.2 Mechanism of Action
 - 11.1.2.3 Regulatory Status
 - 11.1.2.4 Clinical Trial Results
 - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Repatha (Evolocumab) - Amgen
 - 11.1.3.1 Drug Overview
 - 11.1.3.2 Mechanism of Action
 - 11.1.3.3 Regulatory Status
 - 11.1.3.4 Clinical Trial Results
 - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Praluent (Alirocumab)- Sanofi
 - 11.1.4.1 Drug Overview
 - 11.1.4.2 Mechanism of Action
 - 11.1.4.3 Regulatory Status
 - 11.1.4.4 Clinical Trial Results
 - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Nexlizet (Bempedoic Acid And Ezetimibe)- Esperion Therapeutics
 - 11.1.5.1 Drug Overview
 - 11.1.5.2 Mechanism of Action
 - 11.1.5.3 Regulatory Status
 - 11.1.5.4 Clinical Trial Results
 - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

12 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - PIPELINE DRUGS

12.1 List of Atherosclerotic Cardiovascular Disease Pipeline Drugs Across the Top 7 Markets

- 12.1.1 Drug Name – Company Name
 - 12.1.1.1 Drug Overview
 - 12.1.1.2 Mechanism of Action
 - 12.1.1.3 Clinical Trial Results
 - 12.1.1.4 Safety and Efficacy
 - 12.1.1.5 Regulatory Status

Kindly note that the complete list of pipeline drugs has been provided in the report.

13. ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS

14. ATHEROSCLEROTIC CARDIOVASCULAR DISEASE – CLINICAL TRIAL LANDSCAPE

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

15 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - MARKET SCENARIO

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
 - 15.2.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.2.1.1 Market Size (2018-2023)
 - 15.2.1.2 Market Forecast (2024-2034)
 - 15.2.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.2.2.1 Market Size by Therapies (2018-2023)
 - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
 - 15.3.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.3.1.1 Market Size (2018-2023)
 - 15.3.1.2 Market Forecast (2024-2034)
 - 15.3.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.3.2.1 Market Size by Therapies (2018-2023)
 - 15.3.2.2 Market Forecast by Therapies (2024-2034)
 - 15.3.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
 - 15.4.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.4.1.1 Market Size (2018-2023)
 - 15.4.1.2 Market Forecast (2024-2034)
 - 15.4.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.4.2.1 Market Size by Therapies (2018-2023)
 - 15.4.2.2 Market Forecast by Therapies (2024-2034)
 - 15.4.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview
- 15.5 Market Scenario - France

- 15.5.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.5.1.1 Market Size (2018-2023)
 - 15.5.1.2 Market Forecast (2024-2034)
- 15.5.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.5.2.1 Market Size by Therapies (2018-2023)
 - 15.5.2.2 Market Forecast by Therapies (2024-2034)
- 15.5.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
 - 15.6.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.6.1.1 Market Size (2018-2023)
 - 15.6.1.2 Market Forecast (2024-2034)
 - 15.6.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.6.2.1 Market Size by Therapies (2018-2023)
 - 15.6.2.2 Market Forecast by Therapies (2024-2034)
 - 15.6.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
 - 15.7.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.7.1.1 Market Size (2018-2023)
 - 15.7.1.2 Market Forecast (2024-2034)
 - 15.7.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.7.2.1 Market Size by Therapies (2018-2023)
 - 15.7.2.2 Market Forecast by Therapies (2024-2034)
 - 15.7.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
 - 15.8.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.8.1.1 Market Size (2018-2023)
 - 15.8.1.2 Market Forecast (2024-2034)
 - 15.8.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.8.2.1 Market Size by Therapies (2018-2023)
 - 15.8.2.2 Market Forecast by Therapies (2024-2034)
 - 15.8.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
 - 15.9.1 Atherosclerotic Cardiovascular Disease - Market Size
 - 15.9.1.1 Market Size (2018-2023)
 - 15.9.1.2 Market Forecast (2024-2034)
 - 15.9.2 Atherosclerotic Cardiovascular Disease - Market Size by Therapies
 - 15.9.2.1 Market Size by Therapies (2018-2023)
 - 15.9.2.2 Market Forecast by Therapies (2024-2034)
 - 15.9.3 Atherosclerotic Cardiovascular Disease - Access and Reimbursement Overview

16 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS

17 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE MARKET - SWOT ANALYSIS

17.1 Strengths

17.2 Weaknesses

17.3 Opportunities

17.4 Threats

18 ATHEROSCLEROTIC CARDIOVASCULAR DISEASE MARKET – STRATEGIC RECOMMENDATIONS

19 APPENDIX

I would like to order

Product name: Atherosclerotic Cardiovascular Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/ABCB062845BBEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABCB062845BBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

